Home / Top News / Affinia Therapeutics Announces Addition of Gene Therapy Scientific and Medical Experts to Leadership Team to Advance Novel Gene Therapy Platform and Programs to the Clinic
Affinia Therapeutics Announces Addition of Gene Therapy Scientific and Medical Experts to Leadership Team to Advance Novel Gene Therapy Platform and Programs to the Clinic Gene editing expert Charles Albright, Ph.D., joins as chief scientific officer Gene therapy development expert Petra Kaufmann, M.D.,
joins as chief medical officer –
WALTHAM, Mass., Feb. 17, 2021 (GLOBE NEWSWIRE) Affinia Therapeutics, an innovative gene therapy company with a proprietary platform for rationally designed adeno-associated virus (AAV) vectors and gene therapies for rare and non-rare diseases, today announced the completion of its leadership team. Collectively, the executives represent a diverse team of proven leaders in gene therapy who have successfully developed novel platforms and translated the